lapatinib has been researched along with Disease Models, Animal in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (4.76) | 29.6817 |
| 2010's | 34 (80.95) | 24.3611 |
| 2020's | 6 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Abdel Latif, NS; El-Kalaawy, AM; Lamie, PF; Philoppes, JN; Rashed, LA | 1 |
| Chen, T; He, Y; Lu, H; Pang, Z; Wang, Y | 1 |
| El-Khatib, AS; F Mohamed, A; Khattab, MM; Mansour, HM | 1 |
| Ando, K; Cao, X; Wada, T | 1 |
| Chaluvally-Raghavan, P; Geethadevi, A; George, J; Gopinadhan Nair, GK; Kadamberi, IP; Lu, Y; Mills, GB; Nair, A; Nair, B; Parashar, D; Pradeep, S; Rader, JS; Ram, PT; Ramchandran, R; Tsaih, SW; Uyar, DS | 1 |
| Hirata, M; Nezasa, KI; Shinonome, S; Tanaka, H; Tanaka, Y; Torii, M | 1 |
| Brantley-Sieders, DM; Cook, RS; Dimobi, SC; Duvall, CL; Ericsson, PG; Hicks, DJ; Jackson, MA; Joly, MM; Kavanaugh, TE; Kilchrist, KV; Lee, LH; Sanchez, V; Sarett, SM; Wang, S; Werfel, TA | 1 |
| Bode, A; Grubbs, CJ; Juliana, MM; Lubet, RA; Moeinpour, F; Steele, VE | 1 |
| Cheng, AL; Hsieh, PCH; Hsu, WT; Huang, CY; Yen, CYT | 1 |
| Castillo, J; Cejalvo, JM; Cervantes, A; Fleitas, T; Gambardella, V; Gimeno-Valiente, F; Huerta, M; Martinez-Ciarpaglini, C; Roda, D; Roselló, S; Tarazona, N; Tolosa, P | 1 |
| Bachovchin, KA; Bag, S; Buskes, MJ; Ferrins, L; Jalani, HB; Klug, DM; Mehta, N; Mensa-Wilmot, K; Momper, JD; Pollastri, MP; Rodriguez, A; Schneider, KM; Sciotti, RJ; Sharma, A; Singh, B; Tanghe, S | 1 |
| D'Abronzo, LS; Drake, CM; Ghosh, PM; Jathal, MK; Mooso, BA; Siddiqui, S; Steele, TM; Whang, YE | 1 |
| Daschil, N; Datta, S; Doppler, W; Hannesdóttir, L; Koller, JB; Müller-Holzner, E; Parajuli, N; Philipp, S; Sexl, V; Stoitzner, P; Tripp, CH; Tymoszuk, P; Villunger, A; Wasmer, MH; Wiegers, GJ | 1 |
| Galichet, A; Müller, EJ; Rüegg, S; Sayar, BS; Schmidt, E; Sibilia, M; Siffert, M; Suter, MM | 1 |
| Bailey, ST; Bowman, T; Brown, M; Choi, YJ; Debajit, KB; Foley, KM; Iglehart, JD; Kochupurakkal, B; Maulik, G; Miron, A; Miron, PL; Rodig, SJ; Tian, R | 1 |
| Croft, SL; Sanderson, L; Yardley, V | 1 |
| Bartholomeusz, C; Hortobagyi, GN; Humphries, J; Lee, J; Mansour, O; Ordentlich, P; Ueno, NT | 1 |
| Balansky, R; Camoirano, A; D'Agostini, F; De Flora, S; Ganchev, G; Iltcheva, M; Izzotti, A; La Maestra, S; Longobardi, M; Micale, RT; Steele, VE | 1 |
| Bateman, E; Bowen, JM; Boyle, FM; Keefe, DM; Mayo, BJ; Plews, E; Stringer, AM; Wignall, A | 1 |
| Borger, DR; Byron, VF; DiGloria, CM; Foster, R; Groeneweg, JW; Growdon, WB; Hernandez, SF; Kim, M; Lopez, H; Rueda, BR; Scialabba, V; Tambouret, R; Zhang, L | 1 |
| Brown, D; Butowski, N; Cheng, SY; Giles, FJ; James, CD; Mazar, AP; Nicolaides, T; Ozawa, T; Parsa, AT; Raizer, JJ; Sarkaria, JN; Shen, W; Stegh, AH; Yao, TW; Yoshida, Y | 1 |
| Marchetti, D; Ngo, JA; Wetzel, MD; Zhang, L | 1 |
| Akpolat, N; Bulut, H; Demir, T; Kaya, MK; Turgut, B | 1 |
| Chamness, GC; Chang, JC; Contreras, A; De Angelis, C; Fu, X; Giuliano, M; Gray, JW; Gutierrez, C; Heiser, LM; Herrera, S; Hilsenbeck, SG; Hu, H; Lopez-Tarruella, S; Mao, S; Nardone, A; Osborne, CK; Pavlick, AC; Rimawi, MF; Schiff, R; Trivedi, MV; Wang, NJ; Wang, T; Wang, YC | 1 |
| Arribas, J; Aura, C; Boehm, M; Burgues, O; Cortés, J; Deeds, J; Lluch, A; Marangoni, E; Martínez-Barriocanal, Á; Morancho, B; Mosher, R; Navarro Jiménez, A; Nuciforo, P; Peg, V; Rubio, IT; Schlegel, R; Tabernero, J; Vicario, R; Zacarias-Fluck, M; Zhang, J | 1 |
| Halstead-Nussloch, G; Irie, HY; Ito, K; Katsyv, I; Olcott, W; Park, SH | 1 |
| Bertotti, A; Catalano, I; Leto, SM; Migliardi, G; Sassi, F; Throsby, M; Torri, V; Trusolino, L; Zanella, ER | 1 |
| Chen, KF; Chen, MH; Chen, YT; Chu, PY; Hsu, CC; Hsu, CJ; Hu, MH; Huang, CT; Lee, CH; Liu, CY; Shiau, CW; Tsai, WC; Tseng, LM; Wang, DS | 1 |
| Allemand, DH; Charreau, EH; Cidlowski, JA; Cordo Russo, RI; Cortese, E; De Martino, M; Elizalde, PV; Guzmán, P; Huang, TH; Izzo, F; Mercogliano, MF; Oakley, RH; Pereyra, MG; Proietti, CJ; Rivas, MA; Roa, JC; Schillaci, R; Venturutti, L; Yankilevich, P | 1 |
| Conklin, DS; Khan, F; Kokabee, L; Sevinsky, CJ; Sun, Y; Wang, X; Wong, J | 1 |
| Ariza, L; Atencia-Cibreiro, G; Bosch, A; Calvo, AC; Corfas, G; Esteban-Pérez, J; García-Redondo, A; Gregorio, D; Leiva, T; Mancuso, R; Martínez-Muriana, A; Morell, M; Navarro, X; Osta, R | 1 |
| Chen, L; Chen, Z; Fu, L; Li, F; Wang, F; Wang, X; Zhang, W | 1 |
| Bronder, JL; Feigenbaum, L; Gril, B; Herring, JM; Liewehr, DJ; Merino, MJ; Palmieri, D; Rubin, SD; Steeg, PS; Steinberg, SM; Vega-Valle, E | 1 |
| Castellino, S; Chism, JP; Demby, VE; John-Williams, LS; Olson, KL; Otto, V; Polli, JW; Woodard, SM; Yeager, RL | 1 |
| Banat, GA; Cornitescu, T; Dahal, BK; Dumitrascu, R; Ghofrani, HA; Grimminger, F; Kosanovic, D; Pullamsetti, SS; Schermuly, RT; Seeger, W; Tretyn, A; Voswinckel, R; Weissmann, N | 1 |
| Almenara, JA; Campbell, DJ; Dewitt, JL; Oyesanya, RA; Sirica, AE; Zhang, Z | 1 |
| Brasseur, L; Cvitkovic, F; Gutierrez, M; Le Scodan, R; Lyazidi, S | 1 |
| Baykara, M; Benekli, M; Buyukberber, S; Coskun, U; Demirci, U; Kerem, M; Pasali, H; Pasaoglu, H; Uner, A; Yılmaz, G | 1 |
| Ma, F; Westlund, KN; Zhang, L | 1 |
| Bateman, E; Bowen, JM; Boyle, FM; Finnie, JW; Keefe, DM; Mayo, BJ; Plews, E; Stringer, AM | 1 |
| Ager, E; Chung, E; Duyverman, AM; Eichler, AF; Engelman, JA; Farrar, CT; Fukumura, D; Goel, S; Hiddingh, L; Huang, Y; Incio, J; Jain, RK; Kamoun, W; Kodack, DP; Lussiez, A; Mahmood, S; Snuderl, M; Song, Y; Tannous, BA; Yamashita, H | 1 |
1 review(s) available for lapatinib and Disease Models, Animal
| Article | Year |
|---|---|
[Leptomeningeal meningitis related to breast cancer overexpressing HER2: is there a place for a more specific treatment?].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barrier; Breast Neoplasms; Disease Models, Animal; Female; Humans; Lapatinib; Meningeal Carcinomatosis; Meningeal Neoplasms; Primates; Quinazolines; Rats; Receptor, ErbB-2; Trastuzumab | 2011 |
41 other study(ies) available for lapatinib and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
Topics: Animals; Anticonvulsants; Antineoplastic Agents; Apoptosis; Cell Line; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Lithium Carbonate; Male; Mice; Molecular Structure; Pilocarpine; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, ErbB-2; Status Epilepticus; Structure-Activity Relationship | 2021 |
Dual targeting micelles loaded with paclitaxel and lapatinib for combinational therapy of brain metastases from breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Blood-Brain Barrier; Brain; Brain Neoplasms; Breast Neoplasms; Disease Models, Animal; Drug Delivery Systems; Female; Humans; Injections, Intravenous; Lapatinib; Mice; Micelles; Paclitaxel; Peptides; Tumor Cells, Cultured | 2022 |
Lapatinib ditosylate rescues motor deficits in rotenone-intoxicated rats: Potential repurposing of anti-cancer drug as a disease-modifying agent in Parkinson's disease.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Dopaminergic Neurons; Drug Repositioning; Lapatinib; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Rats; Rotenone | 2023 |
Precise safety pharmacology studies of lapatinib for onco-cardiology assessed using in vivo canine models.
Topics: Animals; Antineoplastic Agents; Arrhythmias, Cardiac; Biomarkers; Disease Models, Animal; Dogs; Electrocardiography; Lapatinib; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Safety; Troponin I | 2020 |
Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; ErbB Receptors; Female; Forkhead Box Protein M1; Gene Knockdown Techniques; Humans; Lapatinib; Mice; Ovarian Neoplasms; Peritoneal Neoplasms; Receptor, ErbB-2; Signal Transduction; Thiostrepton; Transfection | 2020 |
Distribution analysis of epertinib in brain metastasis of HER2-positive breast cancer by imaging mass spectrometry and prospect for antitumor activity.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Drug Monitoring; Female; Humans; Lapatinib; Mass Spectrometry; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Tissue Distribution; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Disease Models, Animal; Female; Humans; Lapatinib; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Protein Kinase Inhibitors; Rapamycin-Insensitive Companion of mTOR Protein; Receptor, ErbB-2; RNA, Small Interfering; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models.
Topics: Animals; Disease Models, Animal; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Heterocyclic Compounds, 3-Ring; Lapatinib; Male; Mammary Neoplasms, Experimental; Mice; Mice, Knockout; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Triazoles | 2018 |
The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling.
Topics: Animals; Antineoplastic Agents; Cardiotoxicity; Disease Models, Animal; Doxorubicin; Humans; Lapatinib; Mice; Models, Biological; Myocardium; Myocytes, Cardiac; Nitric Oxide Synthase Type II; Signal Transduction | 2018 |
NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Amplification; Gene Expression Profiling; Humans; Lapatinib; Mice; NF-E2-Related Factor 2; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Receptor, ErbB-2; Ribosomal Protein S6; Signal Transduction; Stomach Neoplasms; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2019 |
Improvement of Aqueous Solubility of Lapatinib-Derived Analogues: Identification of a Quinolinimine Lead for Human African Trypanosomiasis Drug Development.
Topics: Animals; Blood Proteins; Disease Models, Animal; Drug Design; Drug Evaluation, Preclinical; Half-Life; Hepatocytes; Humans; Lapatinib; Mice; Microsomes, Liver; Quinazolines; Rats; Solubility; Structure-Activity Relationship; Thermodynamics; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosomiasis, African; Water | 2019 |
Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Humans; Lapatinib; Male; Mice; Mice, Inbred BALB C; Prostatic Neoplasms, Castration-Resistant; Protein Multimerization; Quinazolinones; Receptor, ErbB-2 | 2019 |
Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response.
Topics: Animals; Antigens, Neoplasm; Breast Neoplasms; CD8-Positive T-Lymphocytes; Cell Movement; Cells, Cultured; Chemotaxis; Disease Models, Animal; Doxorubicin; ErbB Receptors; Female; Humans; In Vitro Techniques; Interferon-gamma; Lapatinib; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Protein Kinase Inhibitors; Quinazolines; Rats; Receptor, ErbB-2; STAT1 Transcription Factor | 2013 |
EGFR inhibitors erlotinib and lapatinib ameliorate epidermal blistering in pemphigus vulgaris in a non-linear, V-shaped relationship.
Topics: Animals; Animals, Newborn; Cells, Cultured; Desmoglein 1; Desmoglein 3; Disease Models, Animal; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Humans; Keratinocytes; Lapatinib; Mice; Mice, Inbred C57BL; Mice, Knockout; Nonlinear Dynamics; Pemphigus; Quinazolines | 2014 |
NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Growth Processes; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mice; Mice, Nude; NF-kappa B; Quinazolines; Receptor, ErbB-2; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Activity of anti-cancer protein kinase inhibitors against Leishmania spp.
Topics: Animals; Antineoplastic Agents; Antiprotozoal Agents; Disease Models, Animal; Drug Repositioning; Indoles; Inhibitory Concentration 50; Lapatinib; Leishmania; Leishmaniasis; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2014 |
A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Benzamides; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Lapatinib; Mice; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Assay of lapatinib in murine models of cigarette smoke carcinogenesis.
Topics: Animals; Antineoplastic Agents; Body Weight; Disease Models, Animal; DNA Adducts; DNA Damage; Erythrocytes; Gene Expression Regulation; Lapatinib; Lung; Lung Neoplasms; Mice; MicroRNAs; Protein Kinase Inhibitors; Quinazolines; Tobacco Smoke Pollution; Toxicity Tests, Subchronic | 2014 |
Determining the mechanisms of lapatinib-induced diarrhoea using a rat model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease Models, Animal; ErbB Receptors; Goblet Cells; Intestinal Mucosa; Intestines; Lapatinib; Male; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; Receptor, ErbB-2 | 2014 |
Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cystadenocarcinoma, Serous; Disease Models, Animal; Female; Gene Amplification; Gene Expression; Humans; Lapatinib; Mice; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Tumor Burden; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2014 |
NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Gene Expression; Glioblastoma; Humans; Lapatinib; Mice; Quinazolines; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression; Gene Knockdown Techniques; Glucuronidase; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Effects of lapatinib and trastuzumab on vascular endothelial growth factor in experimental corneal neovascularization.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Corneal Neovascularization; Corneal Stroma; Disease Models, Animal; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Epithelium, Corneal; Injections, Intraperitoneal; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; Trastuzumab; Vascular Endothelial Growth Factor A | 2015 |
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.
Topics: Animals; Antineoplastic Agents, Hormonal; Biomarkers; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Lapatinib; Mice; Molecular Targeted Therapy; Neoadjuvant Therapy; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays | 2015 |
Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Amplification; Gene Dosage; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Enzyme Activation; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Membrane Proteins; Neoplasm Proteins; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2015 |
Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Gastrointestinal Neoplasms; Gene Amplification; Gene Expression; Gene Knockdown Techniques; Humans; Lapatinib; Mice; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autoantigens; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Humans; Lapatinib; MCF-7 Cells; Membrane Proteins; Mice; Mice, Nude; Promoter Regions, Genetic; Protein Kinase Inhibitors; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2016 |
MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclins; Disease Models, Animal; DNA Helicases; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Lapatinib; Male; Mice; MicroRNAs; Models, Biological; Promoter Regions, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA-Binding Proteins; Stomach Neoplasms; Trastuzumab | 2016 |
Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Epidermal Growth Factor; Female; Gene Expression; Humans; Lapatinib; MAP Kinase Signaling System; Mice; Neuregulin-1; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Neuregulin-1 promotes functional improvement by enhancing collateral sprouting in SOD1(G93A) ALS mice and after partial muscle denervation.
Topics: Amyotrophic Lateral Sclerosis; Animals; Axons; Cell Survival; Disease Models, Animal; Lapatinib; Mice, Transgenic; Motor Neurons; Muscle Denervation; Neuregulin-1; Neurogenesis; Neuromuscular Junction; Quinazolines; Superoxide Dismutase-1 | 2016 |
ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristics.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Disease Models, Animal; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Heterografts; Lapatinib; Mice, Nude; Mitoxantrone; Neoplasm Proteins; Neoplasm Transplantation; Quinazolines; Topotecan | 2017 |
Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunoblotting; Immunochemistry; Lapatinib; Mice; Mice, Inbred BALB C; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Research Design; RNA, Small Interfering; Signal Transduction; Transfection; Xenograft Model Antitumor Assays | 2008 |
An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}meth
Topics: Animals; Antineoplastic Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport; Blood-Brain Barrier; Brain; Breast Neoplasms; Central Nervous System; Cricetinae; Disease Models, Animal; Drug Synergism; Female; Humans; Lapatinib; Male; Mice; Mice, Knockout; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Tissue Distribution | 2009 |
Role of epidermal growth factor inhibition in experimental pulmonary hypertension.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; Hypertension, Pulmonary; Lapatinib; Male; Mice; Muscle, Smooth, Vascular; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pulmonary Wedge Pressure; Quinazolines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Vascular Resistance | 2010 |
Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Disease Models, Animal; ErbB Receptors; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Rats; Receptor, ErbB-2; Signal Transduction; Tyrphostins | 2010 |
Hepatotoxicity associated with lapatinib in an experimental rat model.
Topics: Alanine Transaminase; Albumins; Analysis of Variance; Animals; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Lapatinib; Lipoproteins, VLDL; Liver; Liver Function Tests; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Triglycerides | 2012 |
Trigeminal nerve injury ErbB3/ErbB2 promotes mechanical hypersensitivity.
Topics: Animals; Blotting, Western; Disease Models, Animal; Hyperalgesia; Lapatinib; Male; Neuralgia; Pain Threshold; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Inbred F344; Receptor, ErbB-2; Receptor, ErbB-3; Trigeminal Nerve Injuries; Vibrissae | 2012 |
Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease Models, Animal; Lapatinib; Male; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; Receptor Protein-Tyrosine Kinases | 2012 |
Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Brain Neoplasms; Breast Neoplasms; Cell Death; Cell Proliferation; Diagnostic Imaging; Disease Models, Animal; Female; Gene Amplification; Humans; Killer Cells, Natural; Lapatinib; Mice; Molecular Targeted Therapy; Necrosis; Neovascularization, Pathologic; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Survival Analysis; Trastuzumab; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |